Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Delayed Quote. Delayed  - 10/25 05:40:00 pm
68.52 EUR   -0.98%
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial..
10/25 GLOBAL DIABETIC : Nono Nordisk, Eli Llly, Sanofi, Merk, Tonghua Dong..
10/25SANOFI SA : quaterly earnings release
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial resistance
10/25 GLOBAL DIABETIC NEPHROPATHY (INSULIN : Nono Nordisk, Eli Llly, Sanofi, Merk, Ton..
10/25SANOFI SA : quaterly earnings release
10/21 SANOFI : Genzyme Assigned Patent
10/19 PROMIS NEUROSCIENCES : announces appointment of Dr. Richard Gregory to its Board..
10/18 GLOBAL MENINGOCOCCAL INFECTIONS VACC : Sanofi-Pasteur, Beijing Tiantan Biologica..
10/18 SCHNEIDER ELECTRIC : Three air france apprentices win prizes at altern'up
10/13 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Dupixent® dupilumab Pha..
10/13 SANOFI : Availability of the Pre-quarterly Results Communication
10/12 GLOBAL KETOPROFEN MARKET 2016 : Sanofi, Boehringer Ingelheim, Zhejiang Jiuzhou, ..
More news
Sector news : Pharmaceuticals - NEC
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
10/25 ChemChina ready for concessions to clinch delayed Syngenta deal in 2017 - sou..
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines
10/25DJMARKET SNAPSHOT : U.S. Stock Futures Point To Modest Gains, With Apple Set To Ta..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/18 In Less Than A Month, Regeneron's Luck Kicks In
10/17 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2016 Update
10/14 WALL STREET BREAKFAST : Big Bank Earnings On Tap
10/14 New Zika zone identified in Miami
10/13 BioCryst Pharmaceuticals To The Rescue With Zika Treatment?
Financials (€)
Sales 2016 36 689 M
EBIT 2016 9 188 M
Net income 2016 5 268 M
Debt 2016 5 709 M
Yield 2016 4,32%
P/E ratio 2016 15,59
P/E ratio 2017 14,37
EV / Sales 2016 2,59x
EV / Sales 2017 2,60x
Capitalization 89 207 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 25
Average target price 81,6 €
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.96%97 076
JOHNSON & JOHNSON10.60%310 823
ROCHE HOLDING LTD.-15.88%200 485
NOVARTIS AG-13.71%197 285
PFIZER INC.-0.46%194 889
MERCK & CO., INC.15.01%167 986
More Results